Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


The Fasting Hyperglycaemia Study (FHS) was a six-year, prospective, randomised, placebo-controlled study in subjects who had two consecutive fasting plasma glucose levels in the range 5.5 to 7.7 mmol/L and were thought to be at risk of developing diabetes. The primary aim of the trial was to determine whether deterioration in glycaemic tolerance towards diabetes can be delayed or prevented using an insulin secretagogue (sulphonylurea) or reinforced healthy living advice.


The results of the FHS trial where presented at the EASD meeting in Jerusalem on 19 September 2000.